Revvity Earnings Call: Margin Beat, Portfolio Reset

Revvity, Inc. ((RVTY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Revvity’s latest earnings call struck an upbeat tone as management highlighted better-than-expected Q1 results and rising margins despite pockets of weakness. Executives framed the planned sale of a struggling China diagnostics unit as a key catalyst for cleaner growth and stronger profitability over time, while cautioning about near-term China and software volatility.

Q1 Revenue Beat Masks Stronger Pro Forma Growth

Revvity reported Q1 revenue of $711 million with 3% organic growth, modestly ahead of expectations. Excluding the soon-to-be-divested China immunodiagnostics business, pro forma revenue would have been $687 million, translating into a healthier 6% organic growth pace for the core portfolio.

Margins Outperform and Full-Year Outlook Moves Higher

Adjusted operating margin reached 23.6%, topping the prior 23% outlook as cost actions and mix improvements kicked in. On a pro forma basis, margin was 24%, and management lifted full-year pro forma margin guidance to 28.4%, signaling confidence in continued operating leverage.

EPS Tops Guidance, Reinforcing Profit Momentum

Adjusted EPS came in at $1.06, above the implied guidance range of $1.02 to $1.04 as revenue and margin both outperformed. On a pro forma basis excluding China immunodiagnostics, Q1 adjusted EPS would have been $1.04, still comfortably ahead of internal expectations.

Robust Cash Generation Underpins Balance Sheet Strength

Free cash flow reached $115 million in Q1, converting 97% of adjusted net income and underscoring solid cash discipline. The company ended the quarter with net debt to adjusted EBITDA of 2.8 times and a fully fixed-rate debt stack at a 2.6% average rate and roughly six-year maturity.

China Immunodiagnostics Sale Targets Higher Growth and Margins

Management announced plans to divest the China immunodiagnostics business, which represented about 6% of revenue last year and has been a drag on growth. Pro forma, the exit is expected to lift 2026 organic growth by roughly 100 basis points, improve operating margins by about 30 basis points, and materially enhance cash conversion.

Software and AI Offer a High-Growth Engine

Revvity spotlighted momentum across its software and AI portfolio, including new launches such as Xynthetica, BioDesign, and LabGistics. Management cited roughly 30% to 40% year-over-year ARR growth, a strong SaaS pipeline, and double-digit gains in software APV and SaaS metrics as evidence of durable demand.

Reproductive Health and Instruments Drive Segment Strength

Within diagnostics, reproductive health delivered low double-digit organic growth, with newborn screening also growing at a similar low double-digit clip. In Life Sciences, instrumentation posted mid-single-digit growth, led by strong demand for high-content screening platforms like Opera Phenix OptIQ that benefit from AI-driven research trends.

Capital Returns Signal Confidence in Valuation

The company repurchased $86 million of stock in the quarter, bringing diluted average shares to about 111.9 million. Management reiterated that opportunistic buybacks remain a key capital allocation priority, suggesting confidence in the long-term value of the equity.

China Weakness Weighs on Diagnostics and APAC

China immunodiagnostics faced persistent policy-driven pricing and volume pressures, resulting in meaningful declines. Overall, the China region fell double digits and dragged APAC to a mid-single-digit organic decline, reinforcing management’s rationale for the planned divestiture.

Software Growth to Be Choppy Despite Strong ARR

While subscription metrics remain robust, management warned that reported software growth will be uneven over the next few quarters. After mid-single-digit organic growth in Q1, software is expected to decline about 20% in Q2 on tough comparisons before rebounding to high-teens growth in the second half.

2026 EPS Headwind from China Exit

Removing the China immunodiagnostics unit trims 2026 adjusted EPS guidance by roughly $0.15, with the new pro forma range now $5.20 to $5.30. The reduction reflects the earnings loss from the divested business, partially offset by about $0.05 in operational benefits, and does not assume any contribution from eventual sale proceeds.

Softer FX Tailwind Dampens Top-Line Outlook

Foreign exchange is now expected to provide only about a 50-basis-point benefit to 2026 revenue growth, half the prior assumption of roughly 100 basis points. The reduced tailwind marginally tempers the overall growth profile but does not alter management’s broader strategic narrative.

Deal Timing and Regulatory Risks Around Divestiture

The China immunodiagnostics sale remains at the Letter of Intent stage with a definitive agreement expected in roughly two months. Closing is anticipated by the end of 2027, and until then Revvity will continue reporting the operations while presenting pro forma figures, leaving some execution and regulatory uncertainty.

Cautious Stance for Q2 Despite Strong Start

Pro forma Q2 organic growth is guided to 2% to 3%, with software expected to fall about 20% and Life Sciences roughly flat against tough comparisons. Pro forma revenue is projected at $699 million to $707 million, with margin around 27%, reflecting a deliberately conservative near-term posture.

Guidance Highlights Margin Expansion and Focused Growth

Updated 2026 pro forma guidance calls for 3% to 4% organic growth, a 28.4% adjusted operating margin and EPS of $5.20 to $5.30 on revenue of $2.81 billion to $2.84 billion. Management flagged a modest 50-basis-point FX tailwind and about 75 basis points of growth from the ACD/Labs acquisition, while the divestiture removes roughly 4.5% of prior revenue but is expected to sharpen focus on higher-quality assets.

Revvity’s call painted a picture of a company using portfolio pruning and cost discipline to reset its growth algorithm while absorbing short-term hits. With strong cash generation, rising margins and a growing software and AI franchise, the long-term story remains constructive, though investors must navigate China exposure, choppy software optics and divestiture execution risk in the interim.